Incidence rates of PSV in Jerusalem during a 20-year period (1990–2009) and in quinquennial periods.
| GCA | TA | PAN | All AAV | GPA | MPA | EGPA | |
|---|---|---|---|---|---|---|---|
| No. patients | 140 | 11 | 17 | 43 | 22 | 15 | 6 |
| m:f | 50:90 | 0:11 | 9:8 | 21:22 | 15:7 | 3:12 | 3:3 |
| Mean age (SD) | 75 (5) | 34 (16) | 53 (14) | 59 (11) | 63 (12) | 61 (11) | 48 (9) |
| Incidence* (95% CI): | |||||||
| 1990–2009 | 8.1 (5.7–10.6) | 2.1 (1.2–2.9) | 3.6 (1.6–4.7) | 8.0 (5.2–10.8) | 4.1 (2.2–5.9) | 2.3 (1.2–3.5) | 1.2 (0.4–1.9) |
| 1990–1994 | 10.1 (5.2–14.9) | 1.7 (0–3.7) | 0.9 (0–2.5) | 4.4 (1.7–7.0) | 1.7 (0–3.8) | 1.6 (0–3.5) | 0.9 (0–2.7) |
| 1995–1999 | 14.0 (10.6–17.4) | 2.3 (0.5–4.2) | 3.1 (0.3–6.0) | 6.2 (0–13.6) | 3.1 (0–6.8) | 1.5 (0–3.4) | 1.5 (0–3.4) |
| 2000–2004 | 6.5 (5.1–7.8) | 2.9 (1.5–4.4) | 5.5 (2.2–9.5) | 9.6 (6.7–12.5) | 5.2 (1.5–8.8) | 3.7 (3.6–3.8) | 0.7 (0–1.4) |
| 2005–2009 | 1.9 (0.7–3.2) | 1.4 (0–3.1) | 2.7 (0–6.0) | 11.8 (5.2–18.4) | 6.2 (1.8–10.7) | 4.1 (0.8–7.5) | 1.4 (0–3.1) |
↵* Incidence in GCA cases was calculated per 100,000 adults, age 50 years or older. Incidence rates for other PSV were calculated per 1 million adults, age 20 or older. AAV: ANCA-associated vasculitis: ANCA: antineutrophil cytoplasmic antibodies; EGPA: eosinophilic granulomatosis with polyangiitis; GCA: giant cell arteritis; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; PAN: polyarteritis nodosa; PSV: primary systemic vasculitides; TA: Takayasu arteritis.